Interview
with Neil Love, MD from Breast Cancer Update for Surgeons, Program
1 2000
Play
Audio Below:
I
tend to suggest tamoxifen for most of them. The decision is really an
integration of two trains of thought. One is what’s the likelihood
of recurrence in this cancer and is tamoxifen likely to help that. So,
the more I’m worried about the chance of recurrence, the larger the
tumor, the more the comedo features and so on, the more likely I am to
want to suggest tamoxifen to make sure they don’t have that. The
other train of thought is the prevention one. And that depends on this
person’s age and other factors that we look at in prevention trial.
While I could run the same risk assessment on these people that I do on
the prevention candidates, these people with DCIS may not have such a
background, but when they have certain features like young menarche or
a relative with breast cancer, then I’m certainly going to be more
anxious to give them tamoxifen, but that doesn’t mean that I would
rely only on the risk profile. I would use it as another feature along
with their basic defined risk, which comes from having had this cancer.
Impact
of young age on outcome in patients with ductal carcinoma-in-situ treated
with breast-conserving therapy Vicini, F. A.; Kestin, L. L.; Goldstein, N. S.; Chen, P. Y.; Pettinga,
J.; Frazier, R. C., and Martinez, A. A.. Journal of Clinical Oncology.
18(2):296-306, 2000 Jan.
Carcinoma
in situ of the breast: correlation of histopathology to immunohistochemical
markers and DNA ploidy. Ottesen,
G. L.; Christensen, I. J.; Larsen, J. K.; Larsen, J.; Baldetorp, B.; Linden,
T.; Hansen, B., and Andersen, J. (Reprint available from: Ottesen
GL Univ Copenhagen, Inst Forens Med, Dept Forens Pathol Frederik Vs Vej
11,POB 2713 DK-2100 Copenhagen O Denmark).. Breast Cancer Research &
Treatment. 60(3):219-226, 2000 Apr In process
Application
of the Van Nuys prognostic index in a retrospective series of 367 ductal
carcinomas in situ of the breast examinated by serial macroscopic sectioning:
Practical considerations. de
Mascarel, I.; Bonichon, F.; MacGrogan, G.; de Lara, C. T.; Avril, A.;
Picot, V.; Durand, M.; Mauriac, L.; Trojani, M., and Coindre, J. M. Breast
Cancer Research & Treatment. 61(2):151-159, 2000 May. In process
Postexcision
mammography is indicated after resection of ductal carcinoma-in-situ of
the breast. Waddell, B. E.; Stomper, P. C.; DeFazio, J. L.; Hurd, T. C., and Edge,
S. B. Annals of Surgical Oncology. 7(9):665-668, 2000 Oct. In process
Ductal
carcinoma in situ of the breast: A surgeon's disease. Silverstein, M. J. (Reprint available from: Silverstein MJ Univ So
Calif, Kenneth Norris Jr Comprehens Canc Ctr 1441 Eastlake Ave,Room 7415
Los Angeles, CA 90033 USA). Annals of Surgical Oncology. 6(8):802-810,
1999 Dec. No abstract
Role
of specimen radiography in patients treated with skin-sparing mastectomy
for ductal carcinoma in situ of the breast. Rubio, I. T.; Mirza, N.; Sahin, A. A.; Whitman, G.; Kroll, S. S.;
Ames, F. C., and Singletary, S. E. Annals of Surgical Oncology. 7(7):544-548,
2000 Aug. In process
Carcinoma
in situ of the female breast. 10 year follow-up results of a prospective
nationwide study. Ottesen, G. L.; Graversen, H. P.; Blichert-Toft, M.; Christensen,
I. J., and Andersen, J. A. (Reprint available from: Ottesen GL Univ Copenhagen,
Inst Forens Med, Dept Forens Pathol Frederik Vs Vej 11,POB 2713 DK-2100
Copenhagen Denmark).. Breast Cancer Research & Treatment. 62(3):197-210,
2000 Aug In process
Outcomes
and factors impacting local recurrence of ductal carcinoma in situ. Lagios, M. D. and Silverstein, M. J. (Reprint available from: Lagios
MD St Marys Med Ctr, Breast Canc Consultat Serv San Francisco, CA 94143
USA).. Cancer. 89(11):2323-2324, 2000 Dec 1. In process
Sentinel
lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma-in-situ
and ductal carcinoma-in-situ with microinvasion? Klauber-DeMore, N.; Tan, L. K.; Liberman, L.; Kaptain, S.; Fey, J.;
Borgen, P.; Heerdt, A.; Montgomery, L.; Paglia, M.; Petrek, J. A.; Cody,
H. S., and Van Zee, K. J. Annals of Surgical Oncology. 7(9):636-642, 2000
Oct. In process
Relation
of a recurrent intraductal carcinoma (ductal carcinoma in situ) to the
primary tumor Fisher, E. R. and Fisher, B. (Reprint available from:
Fisher B NSABP Sci Directors Off 4 Allegheny Ctr,Suite 602 Pittsburgh,
PA 15212 USA).. Journal of the National Cancer Institute. 92(4):288-289,
2000 Feb 16. No abstract
